CCA
PDLI

Catalyst Capital Advisors’s PDL BioPharma, Inc. PDLI Stock Holding History

Catalyst Capital Advisors’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-52,000
Closed -$174K – 574
2016
Q3 		$174K Sell
52,000
-28,000
-35% -$88.9K 0.02% 257
2016
Q2 		$251K Buy
+80,000
New +$267K 0.05% 247

Other funds holding PDLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Catalyst Capital Advisors's PDLI Position: Q4 2016 in Review

Catalyst Capital Advisors sold out of PDL BioPharma, Inc. (PDLI) in Q4 2016, closing a stake of 52,000 shares — an estimated $174K sold.

Catalyst Capital Advisors first reported a position in PDLI in Q2 2016 and held it in 2 quarters. The position peaked at $251K in Q2 2016. 190 funds tracked by Wall St. Rank hold PDLI as of Q4 2016.

  • Catalyst Capital Advisors reported no remaining PDL BioPharma, Inc. position as of Q4 2016 after selling out during the quarter.
  • Catalyst Capital Advisors sold 52,000 PDL BioPharma, Inc. shares in Q4 2016, an estimated $174K.
  • Catalyst Capital Advisors first reported a position in PDL BioPharma, Inc. in Q2 2016 and held it in 2 quarters.
  • Catalyst Capital Advisors's PDL BioPharma, Inc. position peaked at $251K in Q2 2016.
  • 190 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2016.

Based on Catalyst Capital Advisors's 13F filing for Q4 2016, filed 8 Feb 2017.